[go: up one dir, main page]

PE20090492A1 - Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3 - Google Patents

Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3

Info

Publication number
PE20090492A1
PE20090492A1 PE2008001205A PE2008001205A PE20090492A1 PE 20090492 A1 PE20090492 A1 PE 20090492A1 PE 2008001205 A PE2008001205 A PE 2008001205A PE 2008001205 A PE2008001205 A PE 2008001205A PE 20090492 A1 PE20090492 A1 PE 20090492A1
Authority
PE
Peru
Prior art keywords
ethyl
alkyl
compounds
pyridazin
imidazo
Prior art date
Application number
PE2008001205A
Other languages
English (en)
Inventor
Ian Bruce
Darren Mark Legrand
James Dale
Thomas Anthony Hunt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38800784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090492(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20090492A1 publication Critical patent/PE20090492A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLOS DE FORMULA (A) DONDE AD ES UN ANILLO HETEROCICLICO AROMATICO 5,6-BICICLICO, EN DONDE A ES UN ANILLO HETEROCICLICO AROMATICO DE 5 MIEMBROS; D ES FENILO O UN ANILLO HETEROCICLICO AROMATICO DE 6 MIEMBROS, DONDE AD ESTA SUSTITUIDO CON R2, R3, R4 Y R5, EN DONDE R2 Y R3 SON CADA UNO H, ALQUILO, SO3H, TIOALQUILO, ENTRE OTROS; R4 Y R5 SON CADA UNO H, HALOGENO, CN, NO2, ALCOXILO, ENTRE OTROS; E ES ARILO(C6-C10), HETEROARILO DE 5 A 10 MIEMBROS O HALOGENO, EN DONDE LOS ANILLOS ESTAN OPCIONALMENTE SUSTITUIDOS CON R6, R7 Y R8, DONDE R6 ES H, HALOGENO, CN, NO2, ENTRE OTROS; R7 Y R8 SON CADA UNO H, ALQUILO, HETEROCICLILO, ARILOXILO, ENTRE OTROS; Q ES O O S; R1 ES H, ALQUILO, ARILO, ALQUIL-AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-[2-(2H-ETIL-2H-TETRAZOL-5-IL)-ETIL]-3-[6-(5-TRIFLUORO-METIL-PIRIDIN-3-IL)-IMIDAZO-[1,2-b]-PIRIDAZIN-2-IL]-UREA, 1-[6-(5-CIANO-PIRIDIN-3-IL)-IMIDAZO-[1,2-b]-PIRIDAZIN-2-IL]-3-[2-(2-ETIL-2H-TETRAZOL-5-IL)-ETIL]-UREA, 1-[6-(PIRIDIN-3-IL)-IMIDAZO-[1,2-b]-PIRIDAZIN-2-IL]-3-[2-(2-ETIL-2H-TETRAZOL-5-IL)-ETIL]-UREA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE CINASA DE FOSFATIDIL-INOSITOL-3 (PI3K) SIENDO UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, OSTEOARTRITIS, ENFERMEDADES TROMBOLITICAS, EMBOLIA, ASMA
PE2008001205A 2007-07-18 2008-07-16 Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3 PE20090492A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07112688 2007-07-18

Publications (1)

Publication Number Publication Date
PE20090492A1 true PE20090492A1 (es) 2009-05-27

Family

ID=38800784

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001205A PE20090492A1 (es) 2007-07-18 2008-07-16 Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3

Country Status (15)

Country Link
US (1) US8053574B2 (es)
EP (1) EP2178868A1 (es)
JP (1) JP2010533680A (es)
KR (1) KR20100049073A (es)
CN (1) CN101801966A (es)
AR (1) AR067562A1 (es)
AU (1) AU2008277628B2 (es)
BR (1) BRPI0813831A2 (es)
CA (1) CA2693232A1 (es)
CL (1) CL2008002097A1 (es)
EA (1) EA201000130A1 (es)
MX (1) MX2010000716A (es)
PE (1) PE20090492A1 (es)
TW (1) TW200908969A (es)
WO (1) WO2009010530A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use
EA201000797A1 (ru) 2007-11-27 2011-02-28 Целльзом Лимитид Аминотриазолы в качестве ингибиторов pi3k
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
NZ588700A (en) * 2008-04-16 2012-07-27 Vertex Pharma Inhibitors of phosphatidylinositol 3-kinase (pi3k)
US20110105457A1 (en) 2008-04-18 2011-05-05 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on pi3k
MX315904B (es) 2008-05-30 2013-11-29 Amgen Inc Inhibidores de fosfoinosituro-3 cinasa.
WO2010010188A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
KR20110096547A (ko) 2008-12-24 2011-08-30 다이이찌 산쿄 가부시키가이샤 고리형 아민 화합물
SG172141A1 (en) 2008-12-24 2011-07-28 Daiichi Sankyo Co Ltd Indanyl compounds
WO2010092015A1 (en) * 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
EP2408773A2 (en) 2009-03-20 2012-01-25 Amgen, Inc Inhibitors of pi3 kinase
JPWO2010125799A1 (ja) 2009-04-27 2012-10-25 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有するウレア誘導体
WO2010133318A1 (en) * 2009-05-20 2010-11-25 Cellzome Ag Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins
BRPI1009637A2 (pt) 2009-06-05 2019-04-30 Cephalon, Inc composto, composição e uso de um composto
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
MX2012000178A (es) * 2009-07-02 2012-02-28 Novartis Ag 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2800664C (en) * 2010-06-01 2019-09-24 Angion Biomedica Corp. Benzothiazole cytochrome p450 inhibitors and therapeutic uses thereof
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
SI2699575T1 (sl) 2011-04-21 2015-10-30 Bayer Intellectual Property Gmbh Triazolopiridini
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015502958A (ja) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド がんの処置のための併用療法
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
ES2605946T3 (es) 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
BR112015000308A2 (pt) 2012-07-10 2017-06-27 Bayer Pharma AG método para preparo de triazolopiridinas substituídas
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
JP6434416B2 (ja) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
JP2016526534A (ja) 2013-06-11 2016-09-05 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジンのプロドラッグ誘導体
WO2015039333A1 (en) * 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CN106488915B (zh) 2014-02-13 2020-10-02 因赛特公司 作为lsd1抑制剂的环丙胺
SG10201806849WA (en) 2014-02-13 2018-09-27 Incyte Corp Cyclopropylamines as lsd1 inhibitors
WO2015134171A1 (en) 2014-03-06 2015-09-11 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of tbk1
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
UA126277C2 (uk) 2015-08-12 2022-09-14 Інсайт Корпорейшн Солі інгібітору lsd1
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
BR112018071585B1 (pt) 2016-04-22 2024-01-02 Incyte Corporation Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas
CN110248938A (zh) 2016-11-23 2019-09-17 拜耳作物科学股份公司 用作农药的2-[3-(烷基磺酰基)-2h-吲唑-2-基]-3h-咪唑并[4,5-b]吡啶衍生物和类似化合物
MA46888A (fr) * 2016-11-28 2021-06-02 Bristol Myers Squibb Co Inhibiteurs de gsk-3
HUE062526T2 (hu) 2017-10-02 2023-11-28 1St Biotherapeutics Inc Benzotiazol vegyületek és azokat alkalmazó eljárások neurodegeneratív rendellenességek kezelésére
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
KR20210122861A (ko) 2019-02-22 2021-10-12 주식회사 퍼스트바이오테라퓨틱스 이미다조피리디닐 화합물 및 증식성 질환의 치료를 위한 그의 용도
WO2020178795A1 (en) * 2019-03-07 2020-09-10 1ST Biotherapeutics, Inc. [ 18f]-labeled benzothiazole derivative as pet radiotracer
US10385046B1 (en) 2019-03-19 2019-08-20 1ST Biotherapeutics, Inc. Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders
CN111116580B (zh) * 2019-12-27 2022-08-23 上海应用技术大学 一种尼麦角林的改进制备方法
EP4284801A4 (en) * 2021-02-01 2025-04-23 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
JP2025510271A (ja) * 2022-03-25 2025-04-14 ファースト・バイオセラピューティクス・インコーポレイテッド 造血前駆細胞キナーゼ１（ｈｐｋ１）阻害剤としてのインダゾールおよびその使用方法
CN118239953A (zh) * 2022-12-23 2024-06-25 中国科学院合肥物质科学研究院 用于治疗PI3Kγ介导的疾病的化合物及其用途
CN119841829A (zh) * 2023-10-18 2025-04-18 中国科学院合肥物质科学研究院 用于治疗PI3Kγ介导的疾病的化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0261459A3 (de) 1986-09-09 1988-05-11 Nihon Tokushu Noyaku Seizo K.K. Neue N-Benzothiazolylamide
IL148998A0 (en) * 1999-10-08 2002-11-10 Gruenenthal Chemie Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring
JP2003521543A (ja) * 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
JP2007529496A (ja) 2004-03-19 2007-10-25 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体
JP2008500284A (ja) * 2004-05-12 2008-01-10 ブリストル−マイヤーズ　スクイブ　カンパニー 血栓症の治療に有用なｐ２ｙ１レセプターのウレアアンタゴニスト
US7636348B2 (en) 2004-06-30 2009-12-22 Bettis Sonny R Distributed IP architecture for telecommunications system with video mail
CA2582482A1 (en) * 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
US7576090B2 (en) * 2004-12-27 2009-08-18 4Sc Ag Benzazole analogues and uses thereof

Also Published As

Publication number Publication date
US8053574B2 (en) 2011-11-08
US20100197682A1 (en) 2010-08-05
EA201000130A1 (ru) 2010-08-30
TW200908969A (en) 2009-03-01
BRPI0813831A2 (pt) 2015-01-06
CL2008002097A1 (es) 2009-02-20
JP2010533680A (ja) 2010-10-28
AR067562A1 (es) 2009-10-14
AU2008277628B2 (en) 2012-03-15
EP2178868A1 (en) 2010-04-28
MX2010000716A (es) 2010-03-26
WO2009010530A1 (en) 2009-01-22
AU2008277628A1 (en) 2009-01-22
CN101801966A (zh) 2010-08-11
KR20100049073A (ko) 2010-05-11
CA2693232A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
PE20090492A1 (es) Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3
PE20091350A1 (es) Derivados de sulfonamidas sustituidas
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20140927A1 (es) Compuestos heterociclicos como inhibidores de cinasas
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20130576A1 (es) Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
PE20110924A1 (es) Derivados de 2, 4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
MX2013007295A (es) Quinoxalinas y aza-quinoxalinas como moduladores del receptor de crth2.
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
PE20170189A1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
PE20091819A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA
PE20121025A1 (es) Compuestos de benzoxazepina como inhibidores de la p13k
PE20130346A1 (es) Compuestos heterociclicos fusionados
CR11738A (es) Compuestos de pirimidinona pirrolo 3-metil-2-imino fenil sustituidos como inhibidores bace-1, composiciones y su uso
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20110411A1 (es) Imidazopiridazinacarbonitrilos como inhibidores de quinasa
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
UY30183A1 (es) Derivados de quinolina
PE20110572A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO INHIBIDORES DE MET

Legal Events

Date Code Title Description
FC Refusal